Raloxifene, a SERM targets PD-L1: an in-silico study

CONCLUSIONS: PD-L1 is a potential target of the SERM raloxifene in-silico. Overall, this study is one step further towards immune checkpoint blockade using small-molecule inhibitors.PMID:37692949 | PMC:PMC10492081

Source: American Journal of Translational Research - September 11, 2023 Category: Research Authors: Chirag Chopra Tenzen Yodun Harpreet Singh Bhupender Singh Shashank K Singh Umesh Goutam Source Type: research